Study: NCT02584478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Taken daily from Day 8 to Day 21 (14 days),administered orally combination with one background chemotherapy in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m\^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m\^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m\^2 intravenously or local standard

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m\^2 intravenously or local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan
Description: Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Weekly Topotecan with a 1 week break every 3 weeks Suggested dose: 4 mg/m2 intravenously or local standard

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan
Description: Weekly Topotecan with a 1 week break every 3 weeks Suggested dose: 4 mg/m2 intravenously or local standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5/6 on Day 1 of each 21-Day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5/6 on Day 1 of each 21-Day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Taken daily from Day 8 to Day 21 (14 days). Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3818
Description: Taken daily from Day 8 to Day 21 (14 days). Administered orally.